|
| Press Releases |
|
 |
|
| Wednesday, September 5, 2018 |
|
|
NANOBIOTIX half year results for the six months ended June 30, 2018 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended June 30 2018, from the consolidated financial statements at June 30, 2018 that have been reviewed by the supervisory board dated September 4, 2018. more info >> |
|
| Friday, July 27, 2018 |
|
|
NANOBIOTIX signs a 40M EUR non-dilutive financing agreement with the European Investment Bank |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company launched a non-dilutive financial partnership with the European Investment Bank (EIB) to boost its research, development and innovation activities. more info >> |
|
| Friday, June 22, 2018 |
|
|
NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today positive topline results of the Phase II/III act.in.sarc trial evaluating NBTXR3 in Soft Tissue Sarcoma (STS). more info >> |
|
| Wednesday, June 6, 2018 |
|
|
NANOBIOTIX' Management Statement on Recent Share Price Variation |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, communicates today regarding the recent evolution of its share price. more info >> |
|
| Friday, May 4, 2018 |
|
|
Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today that it is launching a research collaboration with Weill Cornell Medicine to begin nonclinical studies of NBTXR3's mechanism of action. more info >> |
|
| Wednesday, April 18, 2018 |
|
|
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that preclinical data evaluating the activation of the cGAS-STING pathway by NBTXR3 has been presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago, Illinois (April 14-18, 2018). more info >> |
|
| Wednesday, April 11, 2018 |
|
|
The University of Texas MD Anderson Cancer Center and Nanobiotix have an Agreement to Run Immunotherapeutic Pre-clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it will cooperate with The University of Texas MD Anderson Cancer Center, Houston TX, to work on NBTXR3, Nanobiotix's lead product. more info >> |
|
| Friday, March 30, 2018 |
|
|
Nanobiotix 2017 Annual Results |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2017. more info >> |
|
| Monday, January 22, 2018 |
|
|
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a first readout of intermediate data on the safety and feasibility in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and liver metastasis from other tumors. more info >> |
|
| Thursday, January 11, 2018 |
|
|
Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it will begin a pre-clinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors and activation by radiotherapy. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
CEVA Joins Windrose To Test Long-Haul EV Trucking in China
Jun 28, 2025 01:00 HKT/SGT
|
|
|
CEVA攜手Windrose測試中國長途電動卡車運輸
Jun 28, 2025 01:00 HKT/SGT
|
|
|
CEVA携手Windrose测试中国长途电动卡车运输
Jun 28, 2025 01:00 HKT/SGT
|
|
|
"Tang Vogue Beyond the Horizons: A Golden Era of Multicultural Integration and Openness" exhibition opens
Jun 27, 2025 22:36 HKT/SGT
|
|
|
「唐風萬里：多元交融開放的盛世」展覽開幕
Jun 27, 2025 22:24 HKT/SGT
|
|
|
「唐风万里：多元交融开放的盛世」展览开幕
Jun 27, 2025 22:07 HKT/SGT
|
|
|
Prime Minister Paetongtarn Positions Thailand as Regional AI Ethics Leader: Official Launch of AIGPC at the UNESCO Global Forum on the Ethics of AI 2025
Jun 27, 2025 17:00 HKT/SGT
|
|
|
Honda、2025年5月度 四輪車 生産・販売・輸出実績を発表
Jun 27, 2025 15:15: JST
|
|
|
トヨタ、2025年5月 販売・生産・輸出実績を発表
Jun 27, 2025 13:35: JST
|
|
|
富士通のヘッドレスコマースがファミリーマートの新デジタルコマース事業「ファミマオンライン」を実現
Jun 27, 2025 11:00: JST
|
|
|
GA-ASI Announces Investment in Dutch Technology Innovator Arceon
Jun 27, 2025 01:00 HKT/SGT
|
|
|
GA-ASI 宣布投資荷蘭科技創新公司 Arceon
Jun 27, 2025 01:00 HKT/SGT
|
|
|
IBI Announces 23-Fold Surge in Net Profit for FY2025
Jun 26, 2025 22:37 HKT/SGT
|
|
|
IBI公佈2025財年淨利潤大幅增長23倍 在充滿挑戰的環境中實現強勁業績
Jun 26, 2025 22:24 HKT/SGT
|
|
|
IBI公布2025财年净利润大幅增长23倍 在充满挑战的环境中实现强劲业绩
Jun 26, 2025 22:08 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
